clausenamide: Chinese drug isolated from leaves of Clausena lansium (Lour) Skeels; used in treatment of viral hepatitis; structure given in first source
Flora | Rank | Flora Definition | Family | Family Definition |
---|---|---|---|---|
Lansium | genus | [no description available] | Meliaceae | The mahogany plant family of the order Sapindales, subclass Rosidae, class Magnoliopsida.[MeSH] |
Clausena | genus | A plant genus of the family RUTACEAE. Members contain anethole and CARBAZOLES.[MeSH] | Rutaceae | A plant family in the order Sapindales that grows in warmer regions and has conspicuous flowers.[MeSH] |
Clausena lansium | species | [no description available] | Rutaceae | A plant family in the order Sapindales that grows in warmer regions and has conspicuous flowers.[MeSH] |
ID Source | ID |
---|---|
PubMed CID | 128412 |
CHEMBL ID | 508970 |
SCHEMBL ID | 6369855 |
MeSH ID | M0150381 |
Synonym |
---|
clausenamide |
(+)-clausenamide |
(-)-clausenamide |
CHEMBL508970 |
(3r,4s,5s)-3-hydroxy-5-[(r)-hydroxy(phenyl)methyl]-1-methyl-4-phenylpyrrolidin-2-one |
3-hydroxy-5-[hydroxy(phenyl)methyl]-1-methyl-4-phenylpyrrolidin-2-one |
(3r,4s,5s)-3-hydroxy-5-((r)-hydroxyphenylmethyl)-1-methyl-4-phenylpyrrolidin-2-one |
109905-95-5 |
103541-15-7 |
2-pyrrolidinone,3-hydroxy-5-((r)-hydroxyphenylmethyl)-1-methyl-4-phenyl-, (3r,4s,5s)-rel |
dl-xylonic acid, 3,4-dideoxy-4-(methylamino)-3-phenyl-5-c-phenyl-, gamma-lactam, (s*)- |
neoclausenamide |
zetaclausenamide |
SCHEMBL6369855 |
DTXSID10908462 |
(3r,4s,5s)-3-hydroxy-5-[(r)-hydroxy-phenyl-methyl]-1-methyl-4-phenyl-p yrrolidin-2-one |
Clausenamide is a chiral compound isolated from leaves of the traditional Chinese herb Clausena lansium (lour) Skeels. It has nootropic effects.
Excerpt | Reference | Relevance |
---|---|---|
"Clausenamide is a chiral compound isolated from leaves of the traditional Chinese herb Clausena lansium (lour) Skeels. " | ( (-)Clausenamide facilitates synaptic transmission at hippocampal Schaffer collateral-CA1 synapses. Chen, NH; Han, N; Hu, JF; Ning, N; Sun, JD; Zhang, JT, 2012) | 2.44 |
"(-)clausenamide is a compound isolated from Clausena lansium (lour) Skeel with nootropic effects. " | ( Mechanism of (-)clausenamide induced calcium transient in primary culture of rat cortical neurons. Tang, K; Zhang, JT, 2004) | 1.29 |
"Clausenamide is a compound isolated from Clausena lansium (lour) with the structure similar to piracetam. " | ( [Anti-lipidperoxidation and cerebral protective effects of clausenamide]. Liu, Y; Shi, CZ; Zhang, JT, 1991) | 1.97 |
Clausenamide has been reported to be nootropic and improve learning and memory in amnesia animal models. It has the protective effects against the neurotoxicity induced by okadaic acid and Abeta25-35.
Excerpt | Reference | Relevance |
---|---|---|
"(-)-Clausenamide has been reported to be nootropic and improve learning and memory in amnesia animal models." | ( (-)-Clausenamide alleviated ER stress and apoptosis induced by OGD/R in primary neuron cultures. Chen, J; Cheng, H; Feng, Q; Wu, F; Xue, J; Zhang, R, 2020) | 1.6 |
"(-) Clausenamide has the protective effects against the neurotoxicity induced by okadaic acid and Abeta25-35." | ( [Protective effect of (-) clausenamide against neurotoxicity induced by okadaic acid and beta-amyloid peptide25-35]. Cheng, Y; Zhang, J; Zhang, JT, 2007) | 1.12 |
Excerpt | Reference | Relevance |
---|---|---|
"Clausenamide can enhance the expression of Bcl-2 protein and inhibit apoptosis remarkably." | ( [Effect of clausenamide on the expression of Bcl-2 protein and apoptosis after focal cerebral ischemia/reperfusion in renovascular hypertensive rats]. Bi, GN; Jiang, ZC; Shi, SL, 2005) | 1.44 |
Excerpt | Reference | Relevance |
---|---|---|
"(+) Clausenamide treatment showed no effect on Bmax and KD values." | ( [Effects of (-), (+) clausenamide on central N-methyl-D-asparate receptors in rodents]. Duan, WZ; Zhang, JT, 1997) | 1.1 |
Excerpt | Reference | Relevance |
---|---|---|
" The pharmacokinetic parameters were calculated by 3P97 software." | ( [Pharmacokinetics of (-)-clausenamide and its major metabolite 6-hydroxyl-clausenamide in beagle dogs by HPLC/MS]. Hang, TJ; Qian, W; Song, M; Zhang, ZX, 2005) | 0.63 |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID353954 | Nootropic activity in hippocampus assessed as increase in amplitude of population spikes after 30 mins by long-term potentiation enhancement assay relative to control | 2009 | Bioorganic & medicinal chemistry letters, Apr-15, Volume: 19, Issue:8 | Synthesis and activity in enhancing long-term potentiation (LTP) of clausenamide stereoisomers. |
AID353953 | Nootropic activity in hippocampus assessed as increase in amplitude of population spikes after 15 mins by long-term potentiation enhancement assay relative to control | 2009 | Bioorganic & medicinal chemistry letters, Apr-15, Volume: 19, Issue:8 | Synthesis and activity in enhancing long-term potentiation (LTP) of clausenamide stereoisomers. |
AID353955 | Nootropic activity in hippocampus assessed as increase in amplitude of population spikes after 60 mins by long-term potentiation enhancement assay relative to control | 2009 | Bioorganic & medicinal chemistry letters, Apr-15, Volume: 19, Issue:8 | Synthesis and activity in enhancing long-term potentiation (LTP) of clausenamide stereoisomers. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 1 (2.27) | 18.7374 |
1990's | 9 (20.45) | 18.2507 |
2000's | 20 (45.45) | 29.6817 |
2010's | 12 (27.27) | 24.3611 |
2020's | 2 (4.55) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (27.38) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 2 (4.44%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 43 (95.56%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |